Search | Clinical Trials Finder

Conditions: PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions: Colesevelam, Placebo; Drug
Lead sponsor: University of Rhode Island; Other
Eligibility: 25 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louisville, Kentucky • Augusta, Maine

Conditions: Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions: Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 70 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more

Conditions: Diabetes
Interventions: Colesevelam HCL, Placebo; Drug
Lead sponsor: Carine Beysen; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Walnut Creek, California • Miami, Florida • San Antonio, Texas

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more

Conditions: Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals
Interventions: Colesevelam, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
Interventions: Colesevelam, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nonalcoholic Steatohepatitis
Interventions: Colesevelam Hcl; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Welchol, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 107
States / cities: Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 87 more

Conditions: Multiple Myeloma
Interventions: Serum-derived bovine immunoglobulin/protein isolate (SBI), Colesevelam, Double Placebo; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma, Diarrhea
Interventions: Colesevelam Pill; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 45
States / cities: Birmingham, Alabama • Tuscumbia, Alabama • Little Rock, Arkansas + 42 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Colesevelam, Placebo, Pioglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 141
States / cities: Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 114 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Colesevelam hydrochloride, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions: colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: Minute Maid Heart Wise orange juice, Welchol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and atorvastatin tablets, colesevelam HCl placebo tablets and atorvastatin tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 13
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 10 more

Conditions: Type 2 Diabetes Mellitus
Interventions: High-dose colesevelam, Low-dose colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Colesevelam HCl; Drug
Lead sponsor: KineMed; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more

Conditions: Hypercholesterolemia
Interventions: pravastatin tablets and Welchol tablets, pravastatin tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 15
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 12 more

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 14
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more

Conditions: Fecal Incontinence, Bile Acid Malabsorption
Interventions: Colesevelam, Clonidine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: colesevelam HCl, placebo; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions: Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more

Search by objective public record fields.

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Mechanisms of Glucose Lowering Effect of Colesevelam HCl

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)

Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

Welchol as Monotherapy for Type 2 Diabetes Mellitus

Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.

Colesevelam for Children With Type 2 Diabetes

Effects of Colesevelam HCl On Bile Acid Kinetics

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

A Study of Colesevelam in Fecal Incontinence

Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.